-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

The Promise of Gene Therapy for Severe Hemophilia A

Program: Spotlight Sessions
Session: Gene Therapy and Hemophilia A: What Is the Future of Curative Therapy in the Age of Emicizumab?
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Gene Therapy, Treatment Considerations, Biological therapies, Monoclonal Antibody Therapy
Monday, December 9, 2024, 2:45 PM-4:00 PM

Frank W.G. Leebeek, MD, PhD

Hematology, Erasmus university Medical Center, Rotterdam, Netherlands

Disclosures: Leebeek: SOBI: Research Funding; Biomarin: Consultancy, Other: honoraria for consultancy go to University; CSL Behring: Consultancy, Other: honoraria for consultancy go to University, Research Funding; Takeda: Consultancy, Other: honoraria for consultancy go to University, Research Funding.

See more of: Gene Therapy and Hemophilia A: What Is the Future of Curative Therapy in the Age of Emicizumab?
See more of: Spotlight Sessions
Previous Presentation | Next Presentation >>